MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ANIP made $227,813K in revenue. $26,273K in net income. Net profit margin of 11.53%.

Income Overview

Revenue
$227,813K
Net Income
$26,273K
Net Profit Margin
11.53%
EPS
$1.13
Unit: Thousand (K) dollars
Revenue Breakdown
    • Sales Of Cortrophin Gel
    • Sales Of Generic Pharmaceutical ...
    • Sales Of ILUVIENAnd YUTIQ
    • Others
Revenue Breakdown
    • Rare Disease And Brands
    • Generics And Other

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-06-30
2024-12-31
2024-09-30
Net revenues
227,813 211,371 164,002 148,332
Cost of sales (excluding depreciation and amortization)
93,389 74,615 64,719 63,075
Research and development
12,304 16,535 13,579 10,128
Gain on sale of building
-0 1,337 -
Selling, general, and administrative
76,656 81,771 58,870 79,075
Depreciation and amortization
22,632 23,281 18,643 15,748
Contingent consideration fair value adjustment
-14,470 1,277 -901 825
Loss (gain) on disposal of assets
-295 ---
Intangible asset impairment charge
767 -1,900 -
Total operating expenses, net
191,573 197,479 156,035 168,851
Operating income (loss)
36,240 13,892 7,967 -20,519
Unrealized gain on investment in equity securities
3,140 332 3,832 1,355
Interest expense, net
-4,727 -5,438 -5,307 -2,331
Other (expense) income, net
-853 1,739 -705 -2,535
Loss on extinguishment of debt
0 -0 -7,468
Income (loss) before income tax expense (benefit)
33,800 10,525 5,787 -31,498
Income tax expense (benefit)
7,183 1,976 608 -7,332
Net income (loss)
26,617 8,549 3,966 -24,166
Dividends on series a convertible preferred stock
344 407 406 406
Net income (loss) available to common shareholders
26,273 8,142 3,560 -24,572
Basic income (loss) per share(in dollars per share)
1.19 0.37 0.185 -1.27
Basic weighted-average shares outstanding (in shares)
20,074,000 19,834,000 -9,703,500 19,404,000
Diluted income (loss) per share (in dollars per share)
1.13 0.36 0.185 -1.27
Diluted weighted-average shares outstanding (in shares)
21,093,000 20,308,000 -9,703,500 19,404,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Sales Of ILUVIENAndYUTIQ$16,600K Sales Of CortrophinGel$101,850K Sales Of Royalties AndOther Pharmaceutical...$4,313K Sales Of GenericPharmaceutical Products$94,375K Sales Of EstablishedBrands$10,675K Total Sales Of RareDisease Pharmaceutical...$118,450K Total Sales OfGenerics And Other$98,688K Total Sales Of RareDisease And Brands$129,125K Net revenues$227,813K Unrealized gain oninvestment in equity...$3,140K Operating income (loss)$36,240K Total operatingexpenses, net$191,573K Contingent considerationfair value...-$14,470K Income (loss) beforeincome tax expense...$33,800K Other (expense)income, net-$853K Interest expense, net-$4,727K Intangible assetimpairment charge$767K Loss (gain) ondisposal of assets-$295K Depreciation andamortization$22,632K Selling, general, andadministrative$76,656K Research and development$12,304K Cost of sales(excluding depreciation...$93,389K Net income (loss)$26,617K Income tax expense(benefit)$7,183K Net income (loss)available to common...$26,273K Dividends on series aconvertible preferred stock$344K

ANI PHARMACEUTICALS INC (ANIP)

ANI PHARMACEUTICALS INC (ANIP)